-
Insmed Incorporated recently announced that the European Commission approved BRINSUPRI (brensocatib 25 mg tablets) for treating non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years and older with at least two exacerbations in the past year, marking it as the first and only approved therapy for this condition in the European Union.
-
This regulatory milestone was based on robust evidence from both Phase 2 and Phase 3 studies and followed an accelerated review process, highlighting the therapy’s significance for public health and unmet patient need.
-
We’ll explore how this first-in-class approval for BRINSUPRI may influence Insmed’s commercial outlook and pipeline-driven investment case.
Uncover the next big thing with financially sound penny stocks that balance risk and reward.
For those considering Insmed, the core belief is that the company’s focus on first-in-class therapies can unlock new revenue streams where medical need is high and treatment options are scarce. The European approval of BRINSUPRI for NCFB represents a pivotal regulatory win, but it does not materially change that the U.S. launch remains the single most important near-term catalyst, while delays in U.S. regulatory review and payer access are still key risks.
Among recent developments, Insmed’s August 2025 FDA approval of BRINSUPRI for NCFB in the U.S. stands out, as it set the stage for the upcoming U.S. commercial launch, still seen as the main revenue and growth trigger for the company following the European decision. This persistent focus on regulatory and market access milestones puts the spotlight on execution risks in new market rollouts. Despite major advances, investors should be aware that if the FDA process faces further delays or hurdles,…
Read the full narrative on Insmed (it’s free!)
Insmed’s outlook anticipates $1.9 billion in revenue and $293.8 million in earnings by 2028. This assumes a 72.0% annual revenue growth rate and a $1.21 billion improvement in earnings from the current loss of $-913.8 million.
Uncover how Insmed’s forecasts yield a $214.12 fair value, in line with its current price.
Fair value estimates for Insmed from four Simply Wall St Community members range widely from US$214,118 to over US$21,337,070 per share. With near-term U.S. regulatory and market access still in play, see how other investors are analyzing the company’s risk-reward before making your own assessment.
Explore 4 other fair value estimates on Insmed – why the stock might be worth just $214.12!
